BRANDY JUNKIN: Open Payments
NPI 1902259443 · TUSCALOOSA, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,542 in 79 payments from 19 companies in 2025. Trend: 2023 $1,682 · 2024 $1,640 · 2025 $1,542
Food & beverage: $1,499Education: $43
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 19 | $270 |
| Novo Nordisk Inc | 7 | $208 |
| Otsuka America Pharmaceutical, Inc. | 10 | $172 |
| Vanda Pharmaceuticals Inc. | 6 | $150 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $99 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $93 |
| Neurocrine BioSciences, Inc. | 5 | $92 |
| GlaxoSmithKline, LLC. | 5 | $82 |
| Ardelyx, Inc. | 3 | $65 |
| AstraZeneca Pharmaceuticals LP | 2 | $63 |
Products named: Wegovy, REXULTI, FANAPT, VRAYLAR, CAPLYTA, Kerendia, INGREZZA, SHINGRIX.
Industry payments across AL — which companies pay providers there.
